Cytek Biosciences, Inc. (CTKB)
Nasdaq · Laboratory Analytical Instruments · Manufacturing · CIK 1831915 · fiscal year ends in Dec
Closing price $6.29 on 29 Oct 2026; 52-week range $3.35 to $6.29.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $206.7M
- Revenue growth
- 5.4%
- Net income, last twelve months
- -$80.6M
- Gross margin
- 53.2%
- Operating margin
- -21.6%
- Net margin
- -39.0%
- Free cash flow
- -$12.1M
- Return on equity
- -25.0%
- Market value
- $818.2M
- Cash
- $73.8M
- Debt
- $246.0K
- Debt to equity
- 0.00
- Shares outstanding
- 130.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $201.5M | -$40.4M | -$66.5M | -$0.52 | -$8.8M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $200.5M | -$20.5M | -$6.0M | -$0.05 | $21.9M | 10-K filed 28 Feb 2025 |
| FY2023 | 31 Dec 2023 | $193.0M | -$27.8M | -$12.1M | -$0.09 | $633.0K | 10-K filed 13 Mar 2024 |
| FY2022 | 31 Dec 2022 | $164.0M | -$1.8M | $2.6M | $0.02 | -$22.0M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $2.2M | $9.2M | $3.0M | $0.00 | $266.0K | 10-K filed 17 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $48.1M | -$12.2M | -$0.09 |
| Q1 FY2026 | 31 Mar 2026 | $44.1M | -$18.9M | -$0.15 |
| Q4 FY2025 | 31 Dec 2025 | $62.1M | -$44.1M | -$0.34 |
| Q3 FY2025 | 30 Sep 2025 | $52.3M | -$5.5M | – |
| Q2 FY2025 | 30 Jun 2025 | $45.6M | -$5.6M | -$0.04 |
| Q1 FY2025 | 31 Mar 2025 | $41.5M | -$11.4M | -$0.09 |
| Q4 FY2024 | 31 Dec 2024 | $57.5M | $9.6M | – |
| Q3 FY2024 | 30 Sep 2024 | $51.5M | $941.0K | – |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product | $144.2M | 71.6% |
| Service | $57.3M | 28.4% |
By region, FY2024
| Segment | Revenue | Share |
|---|---|---|
| United States | $92.6M | 46.2% |
| EMEA | $62.3M | 31.1% |
| APAC | $35.8M | 17.8% |
| Other | $9.7M | 4.9% |
Company events
The newest 8-K filings of 46 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 29 Sep 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 24 Aug 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 15 Jul 2026 | 8-K | Leadership change | 5.02 |
| 25 Jun 2026 | 8-K | Leadership change | 5.02 |
| 16 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 2 Jun 2026 | 8-K | Leadership change | 5.02 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 111 held.
| Filed | Form | Period |
|---|---|---|
| 29 Sep 2026 | 8-K | 23 Sep 2026 |
| 24 Aug 2026 | 8-K | 21 Aug 2026 |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 15 Jul 2026 | 8-K | 9 Jul 2026 |
| 25 Jun 2026 | 8-K | 18 Jun 2026 |
| 16 Jun 2026 | 8-K | 10 Jun 2026 |
| 2 Jun 2026 | 8-K | 27 May 2026 |
| 1 Jun 2026 | SD | – |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Sep 2026 | PHILIPPE BUSQUE, Officer | 31,666 | $146.5K | 2 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 6 Aug 2026 | Integrated Core Strategies (US) LLC | 13G amended | 7.2% | 9.3M |
| 4 Aug 2026 | Boston Partners | 13G | 5.91% | 7.6M |
| 8 Jul 2026 | BlackRock, Inc. | 13G amended | 7.2% | 9.4M |
| 18 May 2026 | Integrated Core Strategies (US) LLC | 13G amended | 6.1% | 7.9M |
| 9 Apr 2026 | Millennium Management LLC | 13G | 5.2% | 6.6M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Nov 2025 | Topline Capital Management, LLC | 13G | 5.3% | 6.8M |
| 12 Nov 2025 | Brown Capital Management, LLC | 13G amended | 3.9% | 5.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.4M | -15.45% | 2.68 |
| 30 Sep 2026 | 5.2M | -0.51% | 3.13 |
| 15 Sep 2026 | 5.2M | +6.31% | 5.74 |
| 31 Aug 2026 | 4.9M | -1.17% | 6.64 |
| 14 Aug 2026 | 5.0M | +1.93% | 5.08 |
| 31 Jul 2026 | 4.9M | -2.67% | 7.46 |
| 15 Jul 2026 | 5.0M | +43.41% | 5.46 |
| 30 Jun 2026 | 3.5M | -50.2% | 1.03 |
Funds that hold it
From each fund's latest Form 13F.
192 funds held it at 30 Jun 2026: 69 added and 65 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 9,578,643 | $42.4M | -7,428,626 |
| Millennium Management LLC | 9,338,010 | $41.4M | +3,046,212 |
| Boston Partners | 7,660,943 | $33.9M | +1,858,170 |
| Hhlr Advisors, Ltd | 6,657,030 | $29.5M | 0 |
| Topline Capital Management, LLC | 6,283,450 | $27.8M | -781,031 |
| Vanguard Capital Management LLC | 4,939,597 | $21.9M | +176,693 |
| Geode Capital Management, LLC | 3,059,573 | $13.6M | +225,618 |
| Dimensional Fund Advisors LP | 2,616,257 | $11.6M | -47,072 |
| State Street Corp. | 2,566,121 | $11.4M | -1,557,627 |
| Goldman Sachs Group Inc. | 2,167,515 | $9.6M | -177,220 |
Peers
Companies in the same industry.
- Agilent Technologies, Inc. (A): revenue $7.4B, market value $51.1B
- Waters Corp. (WAT): revenue $4.6B, market value $47.1B
- Illumina, Inc. (ILMN): revenue $4.5B, market value $43.7B
- Mettler Toledo International Inc. (MTD): revenue $4.1B, market value $37.3B
- Revvity, Inc. (RVTY): revenue $2.9B, market value $18.5B
- Avantor, Inc. (AVTR): revenue $6.6B, market value $11.3B
- 10x Genomics, Inc. (TXG): revenue $616.9M, market value $10.4B
- Bio-Rad Laboratories, Inc. (BIO): revenue $2.6B, market value $10.3B
- Bruker Corp. (BRKR): revenue $3.5B, market value $9.4B
- Pacific Biosciences of California, Inc. (PACB): revenue $159.3M, market value $904.5M